InforMax, the Bethesda, Md., maker of the GenoMax enterprise bioinformatics system, has appointed Andrew Whiteley as its new chairman, chief executive officer and president. Whiteley, who will assume his duties on April 1, comes to InforMax from Amersham Biosciences, where he most recently served as vice president of bioinformatics. Whiteley also held positions as vice president of Amersham’s sequencing business, and site director of Amersham International PLC’s Cleveland facility. Whiteley holds bachelor’s degrees in chemistry and biochemistry from the UK’s Nottingham University.
This announcement follows a five-month search to replace InforMax founder and CEO Alex Titomirov, who first announced last October he would be stepping down to pursue other interests. While Titomirov stayed on during this transition, he has now resigned from the InforMax board.
Amplification startup NuGen Technologies of San Carlos, Calif., has appointed David Lowe to its advisory board. Lowe, who is currently the recipient of a Ewing Marion Kauffman fellowship in venture capital and entrepreneurship, previously held R&D positions at Genentech for 16 years, including a term as director of cardiovascular research. Lowe is a co-inventor of a drug currently in clinical trials, and developed a quantitative real-time PCR method that is now widely used. NuGen, which recently raised $10.8 million in a Series B round of financing, is marketing its Single Primer Isothermal Amplification (SPIA) technology.